BUZZ-H.C. Wainwright starts vTv Therapeutics with 'buy' as diabetes drug study set to resume

Reuters2025-04-09

BUZZ-H.C. Wainwright starts vTv <a href="https://laohu8.com/S/LENZ">Therapeutics</a> with 'buy' as diabetes drug study set to resume

** Drug developer vTv Therapeutics' shares VTVT.O rise 3.2% to $16.3 premarket

** Brokerage H.C. Wainwright starts coverage with "buy" rating, sets PT at $36

** The new price target is more than double the stock's last close

** Brokerage says a late-stage study of "underappreciated" diabetes therapy is set to resume in Q2 after the FDA lifted the clinical hold in March 2025

** Company is testing cadisegliatin, an oral adjunctive therapy to insulin for treatment of type 1 diabetes

** Brokerage believes overhang has been lifted from VTVT's shares and company can now enroll the patients in the late-stage study

** Up to last close, stock up 14.4% YTD

(Reporting by Siddhi Mahatole)

((siddhi.mahatole@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2526368673?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-09 19:59","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2526368673","market":"nz","top_or_hot":-1,"title":"BUZZ-H.C. Wainwright starts vTv Therapeutics with 'buy' as diabetes drug study set to resume","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-H.C. Wainwright starts vTv <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> with 'buy' as diabetes drug study set to resume</title></head><body><p>** Drug developer vTv Therapeutics' shares <span>VTVT.O</span> rise 3.2% to $16.3 premarket</p><p>** Brokerage H.C. Wainwright starts coverage with \"buy\" rating, sets PT at $36 </p><p> ** The new price target <span>is </span>more than double the stock's last close</p><p>** Brokerage says a late-stage study of \"underappreciated\" diabetes therapy is set to resume in Q2 after <span>the FDA lifted</span> the clinical hold in March 2025 </p><p>** Company is testing cadisegliatin, an oral adjunctive therapy to insulin for treatment of type 1 diabetes</p><p>** Brokerage believes overhang has been lifted from VTVT's shares and company can now enroll the patients in the late-stage study</p><p>** Up to last close, stock up 14.4% YTD</p><p>(Reporting by Siddhi Mahatole)</p><p>((siddhi.mahatole@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-H.C. Wainwright starts vTv Therapeutics with 'buy' as diabetes drug study set to resume</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-H.C. Wainwright starts vTv Therapeutics with 'buy' as diabetes drug study set to resume\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-04-09 19:59</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-H.C. Wainwright starts vTv <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> with 'buy' as diabetes drug study set to resume</title></head><body><p>** Drug developer vTv Therapeutics' shares <span>VTVT.O</span> rise 3.2% to $16.3 premarket</p><p>** Brokerage H.C. Wainwright starts coverage with \"buy\" rating, sets PT at $36 </p><p> ** The new price target <span>is </span>more than double the stock's last close</p><p>** Brokerage says a late-stage study of \"underappreciated\" diabetes therapy is set to resume in Q2 after <span>the FDA lifted</span> the clinical hold in March 2025 </p><p>** Company is testing cadisegliatin, an oral adjunctive therapy to insulin for treatment of type 1 diabetes</p><p>** Brokerage believes overhang has been lifted from VTVT's shares and company can now enroll the patients in the late-stage study</p><p>** Up to last close, stock up 14.4% YTD</p><p>(Reporting by Siddhi Mahatole)</p><p>((siddhi.mahatole@thomsonreuters.com))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250409:nL3N3QN1B6:1","article_id":"2526368673","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2526368673","pubTimestamp":1744199954,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-H.C. Wainwright starts vTv Therapeutics with 'buy' as diabetes drug study set to resume** Drug developer vTv Therapeutics' shares VTVT.O rise 3.2% to $16.3 premarket** Brokerage H.C. Wainwright starts coverage with \"buy\" rating, sets PT at $36  ** The new price target is more than double the stock's last close** Brokerage says a late-stage study of \"underappreciated\" diabetes therapy is set to resume in Q2 after the FDA lifted the clinical hold in March 2025 ** Company is testing cadisegliatin, an oral adjunctive therapy to insulin for treatment of type 1 diabetes** Brokerage believes overhang has been lifted from VTVT's shares and company can now enroll the patients in the late-stage study** Up to last close, stock up 14.4% YTD","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","VTVT":"vTv Therapeutics Inc."},"translate_title":"巴斯-H.C。随着糖尿病药物研究即将恢复，Wainwright以“买入”方式启动vTv Therapeutics","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VTVT":0.9},"content_text":"BUZZ-H.C. Wainwright starts vTv Therapeutics with 'buy' as diabetes drug study set to resume** Drug developer vTv Therapeutics' shares VTVT.O rise 3.2% to $16.3 premarket** Brokerage H.C. Wainwright starts coverage with \"buy\" rating, sets PT at $36  ** The new price target is more than double the stock's last close** Brokerage says a late-stage study of \"underappreciated\" diabetes therapy is set to resume in Q2 after the FDA lifted the clinical hold in March 2025 ** Company is testing cadisegliatin, an oral adjunctive therapy to insulin for treatment of type 1 diabetes** Brokerage believes overhang has been lifted from VTVT's shares and company can now enroll the patients in the late-stage study** Up to last close, stock up 14.4% YTD(Reporting by Siddhi Mahatole)((siddhi.mahatole@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2526368673","isCrawlerRequest":true}